Inventiva S.A.
http://www.inventivapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inventiva S.A.
Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Inventiva’s Lanifibranor On NASH Path After Phase II Success In NAFLD Patients With Diabetes
The French biotech’s PPAR agonist has significantly reduced liver fat in non-alcoholic fatty liver patients with type 2 diabetes in a mid-stage trial, raising hopes for success in an ongoing pivotal program in non-alcoholic steatohepatitis.
Inventiva Revises Phase III NASH Plans For Broader Indication
While plans to obtain accelerated approval of lanifibranor remain unchanged, Inventiva now plans to conduct the confirmatory Phase III in cirrhotic patients, meaning a shorter trial duration and possibly broader label.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Inventiva Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice